Navigation Links
Renaissance in new drugs for rare diseases: Report in world's largest scientific socity magazine
Date:5/13/2013

ther driving force. They are directly funding some research, and they're working smarter and getting creative about drawing attention and dollars for research. Deeper insights into the genetics of these disorders and federal legislation extending patent protection for these medicines also have helped.

Jarvis spent time with several families of children dealing with rare diseases, saw their passion first-hand and includes their stories in the article.

It describes how venture capital firms have become engaged in funding research on rare diseases to the point where more venture capital money may be going toward drugs for rare diseases than for any other type of medication, except for cancer drugs.

Most of the 7,000 rare diseases result from genetic defects, and about half of those affect children. In some cases, children die before they reach adulthood without treatment. Many of the rarest of these diseases affect only a few dozen to a few thousand people. Hunter syndrome, for instance, affects fewer than 500 boys in the U.S., and Gaucher's disease affects about 5,000 people.

Misdiagnosis is a common theme, Jarvis writes. It takes the typical patient 7.6 years and consultations with eight physicians to finally discover what's really going on.

Jarvis reports that until recently, pharmaceutical companies often focused on "blockbuster" drugs, medicines for common conditions like high cholesterol, high blood pressure and diabetes that would have annual sales of at least $1 billion. However, companies like Genzyme, a subsidiary of Sanofi, showed that medications for rare diseases can make money by pricing them high enough to cover research and development costs, and having insurance companies reimburse most patient costs. That's an attractive scenario for larger companies, which are getting into the market, even creating special units focused on this segment, Jarvis adds.

Scientists know more about rare diseases tha
'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference
2. Nanopills release drugs directly from the inside of cells
3. Genetic variation in East Asians found to explain resistance to cancer drugs
4. Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
5. Internet and new drugs: A challenge for public health
6. Study raises questions about use of anti-epilepsy drugs in newborns
7. Drugs from lizard saliva reduces the cravings for food
8. A new method detects traces of veterinary drugs in baby food
9. La Jolla Institute discovery could lead to new way to screen drugs for adverse reactions
10. MIT-designed cooler preserves tuberculosis drugs, records doses
11. Arsenic for better drugs and cleaner crops
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... the National Institute of Standards and Technology (NIST), ... dramatically improved technique for analyzing biological cells and ... new NIST technique is an advanced form of ... that delivers signals that are 10,000 times stronger ... times stronger than obtained from comparable "coherent Raman" ...
(Date:7/22/2014)... N.C. In a cost-effectiveness analysis of commercial diet ... drug Qsymia showed the best value for the money. ... but was also the most expensive option tested, according ... Medical School. , The findings, published in the June ... information on the health and weight-loss benefits per dollar ...
(Date:7/22/2014)... Buccola, MSN, APRN, PMHCNS-BC, CNE, Assistant Professor of ... Orleans School of Nursing, contributed samples used in ... associated with schizophrenia and also suggesting a possible ... study, Biological insights from 108 schizophrenia-associated genetic loci, ... Nature , available at http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13595.html., ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3LSUHSC contributes to work identifying new DNA regions associated with schizophrenia 2
... Bio-Technology Group Co., Inc. (OTC Bulletin Board: ... leading developer, manufacturer and marketer of Traditional Chinese ... other health and nutritional products in the People,s ... its private placement offering for aggregate gross proceeds ...
... In order for medical students to ultimately provide quality patient ... teach physiology, one of the core disciplines of medicine, according ... Journal of the American College of Radiology ( www.jacr.org ... systems. "It is vital that medical schools provide ...
... Avantra Biosciences (Avantra) today announced the selection ... test site for Avantra,s new biomarker quantitation platform. ... has created an automated multiplex immunoassay system to ... patient characteristics, and drug responses. The new Q400 ...
Cached Biology News:Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 3Avantra Biosciences teams with TGen Drug Development to assist pharma 2
(Date:7/22/2014)... LANSING, Mich., July 22, 2014  Neogen Corporation (NASDAQ: ... its 2014 fiscal year, which ended May 31, increased ... net income was $28,158,000, compared to the prior year,s ... 30, 2013, earnings per share in the current year ... revenues and net income for the 2014 fiscal year ...
(Date:7/22/2014)... , July 22, 2014 Hussey Copper ... MD-Cu 29 antimicrobial copper announces Pullman Regional Hospital,s ... first EPA-registered antimicrobial solid touch surface, at a nominal ... of MRSA, E-coli and other bacteria within 2 hours of ... protecting against bacteria and infectious diseases in its facilities. ...
(Date:7/22/2014)... July 22, 2014  United Therapeutics Corporation (NASDAQ: ... will release its second quarter 2014 financial results ... United Therapeutics will host a half-hour ... a.m. Eastern Time.  The teleconference is accessible by ... rebroadcast of the teleconference will be available for ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Dr. Williams ... those who have recognized that the greatest health care ... far too often needlessly deadly while trying to serve ... of quasi-experts seeking to transform an enormous system that ... Dr. Williams, in his continuing series of Open Letters ...
Breaking Biology Technology:Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2
... in Key Markets, Differentiated Product Offerings and ... Performance, CARY, N.C., Jan. 10 ... significant milestone with the signing of its ... additional customers during the,second half of 2007. ...
... LONDON, January 10 Amarin Corporation plc,(NASDAQ: AMRN ... and ethical approvals to commence a Phase IIa trial ... The Phase IIa trial will be a randomized, ... AAMI who,will be randomized to receive 1, 2 or ...
... Essilor International,s US subsidiary, has strengthened its,prescription laboratory ... Interstate Optical Co., one of the country,s five ... and,Indianapolis, Indiana serve eye care professionals in 32 ... and 210 employees., Present for more than ...
Cached Biology Technology:SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations 2SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations 3SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations 4Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 2Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 3Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 4
...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
... (patent pending) was developed using a protein engineering ... DNA binding pocket of wild-type DNase I. These ... for DNA. The result is a versatile enzyme ... and an ability to maintain at least 50% ...
Request Info...
Biology Products: